Clinical Trials Logo

Hepatocellular Carcinoma clinical trials

View clinical trials related to Hepatocellular Carcinoma.

Filter by:

NCT ID: NCT03781934 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations

Start date: September 5, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicentre, open-label study to assess safety and tolerability of MIV-818 in patients with various solid tumours that have spread to the liver, or alternatively originating in the liver.

NCT ID: NCT03780634 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC

Start date: December 18, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared with HAIC plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03780049 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B

Start date: October 1, 2018
Phase: Phase 3
Study type: Interventional

Hepatic artery infusion chemotherapy (HAIC) is effective and safe for hepatocellular carcinoma (HCC). Recombinant Human Type-5 Adenovirus (H101) is safe for HCC. The purpose of this study is to evaluate the efficacy and safety of HAIC combined with H101 compared with HAIC alone in patients with unresectable hepatocellular carcinoma (HCC) at barcelona clinic liver cancer A-B stage.

NCT ID: NCT03778957 Recruiting - Clinical trials for Hepatocellular Carcinoma

A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma

EMERALD-1
Start date: November 30, 2018
Phase: Phase 3
Study type: Interventional

A global study to evaluate transarterial chemoembolization (TACE) in combination with durvalumab and bevacizumab therapy in patients with locoregional hepatocellular carcinoma

NCT ID: NCT03777475 Recruiting - Clinical trials for Hepatocellular Carcinoma

the Effect of Different Oxaliplatin Dose in Transarterial Infusion (TAI) in Unresectable Hepatocellular Carcinoma

Start date: July 1, 2016
Phase: N/A
Study type: Interventional

evaluate the effect of different oxaliplatin dose in TAI in treating unresectable HCC.

NCT ID: NCT03775707 Recruiting - Clinical trials for Hepatocellular Carcinoma

Lenvatinib Plus PD-1 Antibody for Intermediate-stage HCC Beyond Up-to-seven Criteria

Start date: December 1, 2018
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with PD-1 antibody for patients with intermediate-stage hepatocellular carcinoma (HCC) beyond up-to-seven criteria

NCT ID: NCT03775395 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Plus Lenvatinib vs HAIC Plus Sorafenib for Advanced HCC

Start date: December 12, 2018
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of sorafenib combined with hepatic arterial infusion chemotherapy (HAIC) compared with lenvatinib combined with HAIC in patients with advanced hepatocellular carcinoma (HCC)

NCT ID: NCT03767764 Recruiting - Clinical trials for Hepatocellular Carcinoma

Yliver as a Test to Early Diagnose HCC

YliverDIAG
Start date: December 27, 2018
Phase:
Study type: Observational

Liver cancer (HCC) is the second cause of death related to cancer worldwide, with about 750,000 deaths from this cause in 2012. Although the early diagnosis of liver cancer increases the available treatment options, the methods currently used for screening are not sufficiently sensitive for this purpose. The investigators provide a high-performance and highly reliable in vitro platform that allows the identification and quantification of autoantibodies in serum for use as biomarkers of liver cancer, using an ELISA test (Yliver). The aim of the study is to demonstrate whether the Yliver test can be used as a biomarker for the early diagnosis of hepatocellular carcinoma with a collection of samples from 58 patients diagnosed with HCC, 42 cirrhosis, 40 normal controls and the inclusion of 25-50 patients with chronic liver disease without cirrhosis.

NCT ID: NCT03755791 Recruiting - Clinical trials for Hepatocellular Carcinoma

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy

COSMIC-312
Start date: December 1, 2018
Phase: Phase 3
Study type: Interventional

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy. An exploratory arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

NCT ID: NCT03754192 Not yet recruiting - Clinical trials for Hepatocellular Carcinoma

Perfusion and Dual Energy Computer Tomography in Hepatocellular Carcinoma

PERCAHEC
Start date: December 30, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the hepatic perfusion computer tomography and dual energy computer tomography in the assessment of tumor characterization of Hepatocellular carcinoma in patients with resectable Hepatocellular carcinoma by comparing the quantitative parameters computer tomography obtained with the pathological data of the surgical specimens.